# Prademagene PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/prademagene

> The FDA approved prademagene, sponsored by ABEONA THERAPEUTICS INC. (ABEO), on April 29, 2025 for wounds in adult and pediatric patients with RDEB.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is prademagene FDA approved?

Yes. The FDA approved prademagene, sponsored by ABEONA THERAPEUTICS INC. (ABEO), on April 29, 2025 for wounds in adult and pediatric patients with RDEB. Press release filed with the SEC (EX-99): "April 29, 2025 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved" [Calendar and source filings](https://sec-api.dev/pdufa/prademagene)

Source: Press release filed with the SEC (EX-99), accession 0001641172-25-006548, https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2025-08-14. Cite: https://sec-api.dev/pdufa/prademagene#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | prademagene |
| Codes |  |
| Sponsor | ABEONA THERAPEUTICS INC. (ABEO) https://sec-api.dev/companies/abeo/catalysts |
| Indications | wounds in adult and pediatric patients with rdeb |
| Modality | gene_therapy |
| FDA designations | none disclosed |

## Timeline

### April 16, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 04/16/2024 for BL 125807 to Abeona Therapeutics, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125807_20240416.pdf%22

### April 29, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001493152-24-044514): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025." https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-24-044514): "FDA assigns PDUFA target action date of April 29, 2025" https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-010514): "FDA approval of first-in-class RDEB therapy: On April 28, 2025, the U.S. FDA approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB." https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/ex99-1.htm

### April 29, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: wounds in adult and pediatric patients with RDEB.
- First seen 2025-04-29, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-010514): "FDA approval of first-in-class RDEB therapy: On April 28, 2025, the U.S. FDA approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB." https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-006548): "April 29, 2025 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved" https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-023715): "FDA approval of first-in-class RDEB therapy: In April 2025, the U.S. FDA approved" https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/prademagene.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Prademagene PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/prademagene

```bibtex
@misc{secapidev_pdufa_prademagene_20261116,
  title        = {Prademagene PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/prademagene}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_prademagene_20261116","title":"Prademagene PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/prademagene","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
